HPV 16/18 vaccination to prevent cervical cancer In The Netherlands: Model-based cost-effectiveness

International Journal of Cancer

Volumn 124, Issue 4, 2009, Pages 970-978

  Coupe, Veerle M H ^a   Van Ginkel, Joost ^a   De Melker, Hester E ^b   Snijders, Peter J F ^a   Meijer, Chris J L M ^a   Berkhof, Johannes ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Epidemiology and Surveillance Unit   (Netherlands)

Author keywords

Cervicalcancer; Human papillomavirus; Simulationmodel; Vaccination

Indexed keywords

WART VIRUS VACCINE;

ARTICLE; CANCER IMMUNIZATION; CANCER MORTALITY; CANCER PREVENTION; CANCER SCREENING; COHORT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DISEASE ASSOCIATION; DRUG COST; DRUG EFFICACY; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; INFECTION RISK; NETHERLANDS; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SIMULATION; UTERINE CERVIX CANCER; ADOLESCENT; ADULT; CANCER DIAGNOSIS; CHILD; COMPUTER SIMULATION; COST BENEFIT ANALYSIS; ECONOMICS; FEMALE; HUMAN; IMMUNOLOGY; MIDDLE AGED; UTERINE CERVIX TUMOR; VACCINATION; VIROLOGY; VIRUS INFECTION;

ADOLESCENT; ADULT; CHILD; COMPUTER SIMULATION; COST-BENEFIT ANALYSIS; EARLY DETECTION OF CANCER; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; QUALITY-ADJUSTED LIFE YEARS; UTERINE CERVICAL NEOPLASMS; VACCINATION;

EID: 58149474533     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24000     Document Type: Article

References (52)

1. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, Snijders PJ, Meijer CJ. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:518-27.
2. The Future II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007;356:1915-27.
3. Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM, Jenkins D, Schuind A, Costa Clemens SA, Dubin G. Sustained efficacy up to 4.5 years of a bivalent LI viruslike particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 20O6;367:1247-55.
4. Bosch FX, Manos MM, Munoz N, Sherman M, Jansen AM, Peto J, Schiffraan MH, Moreno V, Kurman R, Shah KV. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst 1995;87:796-802.
5. Clifford GM, Smith JS, Aguado T, Francesehi S. Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Br J Cancer 2003;89:101-5.
6. Ault KA. Effect of prophylactic human papillomavirus LI virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 2007;369:1861-8.
7. Paavonen J, Jenkins D, Bosch FX, Nand P, Salmeron J, Wheeler CM, Chow SN, Apter DL, Kitchener HC, Castellsague X, De Carvalho NS, Skinner SR, et al. Efficacy of a prophylactic adjuvanted bivalent LI virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007:369: 2161-70.
8. Olsson SE, Villa LL, Costa RE, Petta CA, Andrade RP, Malm C, Iversen OE, Hove J, Steinwail M, Riis-Johannessen G, Andersson-Ell-strom A, Elfgren K, et al. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) tvpes 6/11/16/18 LI virus-like particle (VLP) vaccine. Vaccine 2007;25:4931-9.
9. Elbasha EH, Dasbaeh EJ, Insinga RP. Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis 2007;13:28-41.
10. Goldie SJ, Kohli M, Grima D, Weinstein MC, Wright TC, Bosch FX, Franco E. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Tnst 2004;96: 604-15.
11. Kulasingara SL, Myers ER. Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA 2003;290:781-9.
12. Sanders GD, Taira AV. Cost-effectiveness of a potential vaccine for human papillomavirus. Emerg Infect Dis 2003;9:37-t8.
13. Kohli M, Ferko N, Martin A, Franco EL, Jenkins D, Gallivan S, Sher-law-Johnson C, Drumraond M. Estimating the long-term impact of a prophylactic human papillomavirus 16/18 vaccine on the burden of cervical cancer in the UK. Br J Cancer 2007;96:143-50.
14. Brisson M, van de Velde N, de Wals P, Body MC. The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada. Vaccine 2007;25:5399-408.
15. Bulkraans NW, Berkhof J, Bulk S, Bleeker MC, van Kemenade FJ, Rozendaal L, Snijders PJ, Meijer CJ. High-risk HPV type-specific clearance rates in cervical screening. Br J Cancer 2007;96:1419-24.
16. Bulkmans NW, Berkhof J, Rozendaal L, van Kemenade FJ, Boeke AJ, Bulk S, Voorhorst FJ, Verheijen RH, van Groningen K, Boon ME, Ruitinga W, van Ballegooijen M. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-vear follow-up of a randomised controlled implementation trial. Lancet 2007;370:1764-72.
17. Coupe VM, Berkhof J, Bulkmans NW, Snijders PJ, Meijer CJ. Age-dependent prevalence of 14 high-risk HPV types in The Netherlands: implications for prophylactic vaccination and screening. Br. J Cancer 2008:98:646-51.
18. Berkhof J, de Bruijne MC, Zielinski GD, Meijer CJ. Natural history and screening model for high-risk human papillomavirus infection, neoplasia and cervical cancer in The Netherlands. Int J Cancer 2005:115:268-75.
19. Berkhof J, Bulkmans NW, Bleeker MC, Bulk S, Snijders PJ, Voorhorst FJ, Meijer CJ. Human papillomavirus type-specific 18-month risk of high-grade cervical intraepithelial neoplasia in women with a normal or borderline/mildlv dyskaryotic smear. Cancer Epidemiol Biomarkers Prev 2006; 15:1268-73.
20. Bulk S, Bulkmans NW, Berkhof J, Rozendaal L, Boeke AJ, Verheijen RH, Snijders PJ, Meijer CJ. Risk of high-grade cervical intra-epithe-lial neoplasia based on cytology and high-risk HPV testing at baseline and at 6-raonths. Int J Cancer 2007;121:361-7.
21. Rozendaal L, Walboomers JM, van der Linden JC, Voorhorst FJ, Kenemans P, Heimerhorst TJ, van Ballegooijen M, Meijer CJ. PCR-based high-risk HPV test in cervical cancer screening gives objective risk assessment of women with cytomorphologically normal cervical smears. Int J Cancer 1996;68:766-9.
22. Rozendaal L, Westerga J, van der Linden JC, Walboomers JM, Voorhorst FJ, Risse EK, Boon ME, Meijer CJ. PCR based high risk HPV testing is superior to neural network based screening for predicting incident CIN I IT in women with normal cytology and borderline changes. J Clin Pathol 2000;53:606-11.
23. Gok M, Coupe VM, Berkhof J, Verheijen RH, Heimerhorst TJ, Hoge-woning CJ, Snijders PJ, Meijer CJ. HPV16 and increased risk of recurrence after treatment for CIN. Gynecol Oncol 2007;104:273-5.
24. Nobbenhuis MA, Walboomers JM, Heimerhorst TJ, Rozendaal L, Remmink AJ, Risse EK, van der Linden HC, Voorhorst FJ, Kenemans P, Meijer CJ. Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study. Lancet 1999;354:20-5.
25. Nobbenhuis MA, Heimerhorst TJ, van den Brule AJ, Rozendaal L, Voorhorst FJ, Bezemer PD, Verheijen RH, Meier CJ. Cytological regression and clearance of high-risk human papillomavirus in women with an abnormal cervical smear. Lancet 2001;358:1782-3.
26. Bulk S, Berkhof J, Bulkmans NW, Zielinski GD, Rozendaal L, van Kemenade FJ, Snijders PJ, Meijer CJ. Preferential risk of HPV 16 for squamous cell carcinoma and of HPV 18 for adenocarcinoma of the cervix compared to women with normal cytologv in The Netherlands. Br J Cancer 2006;94:171-5.
27. Bulk S, Berkhof J, Rozendaal L, Fransen Daalraeijer NC, Gok M, de Schipper FA, van Kemenade FJ, Snijders PJ, Meijer CJ. The contribution of HPV 18 to cervical cancer is underestimated using high-grade CIN as a measure of screening efficiency. Br J Cancer 2007:96:1234-36.
28. Retting BW. Surgical treatment of invasive carcinoma of the uterine cervix. Amsterdam: University of Amsterdam, 1981. 154.
29. van den Akker-van Marie ME, van BM, van Oortraarssen GJ, Boer R, Habberaa JD. Cost-effectiveness of cervical cancer screening: comparison of screening policies. J Natl Cancer Inst 2002:94:193-204.
30. Mandelblatt JS, Lawrence WF, Woraack SM, Jacobs D, Yi B, Hwang YT, Gold K. Barter J. Shah K. Benefits and costs of using HPV testing to screen for cervical cancer. JAMA 2002;287:2372-81.
31. Berkhof J, de Bruijne MC, Zielinski GD, Bulkmans NW, Rozendaal L, Snijders PJ, Verheijen RH, Meijer CJ. Evaluation of cervical screening strategies with adjunct high-risk human papillomavirus testing for women with borderline or mild dyskaryosis. Int J Cancer 2006;118:1759-68.
32. van Ballegooijen M, Rebolj M, Essink-Bot ML, Meerding WJ, Berkers LM, Habbema JDF. De effected en kosten van het bevolking-sonderzoek naar baarraoederhalskanker in Nederland na de herstruc-turering. Rottterdam; Erasmus MC, 2006.
33. Nobbenhuis MA, Meijer CJ, van den Brule AJ, Rozendaal L, Voorhorst FJ, Risse EK, Verheijen RH, Heimerhorst TJ. Addition of high-risk HPV testing improves the current guidelines on follow-up after treatment for cervical intraepithelial neoplasia. Br J Cancer 2001; 84:796-801.
34. Zielinski GD, Snijders PJ, Rozendaal L, Voorhorst FJ, Runsink AP, de Schipper FA, Meijer CJ. High-risk HPV testing in women with borderline and mild dyskaryosis: long-term follow-up data and clinical relevance. J Pathol 2001;195:300-6.
35. Sherman ME, Lorincz AT, Scott DR, Wacholder S, Castle PE, Glass AG, Mielzynska-Lohnas I, Rush BB, Schiffman M. Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis. J Natl Cancer Inst 2003;95:46-52.
36. Ostor AG. Natural history of cervical intraepithelial neoplasia: a critical review. Tnt J GynecofPathol 1993; 12:186-92.
37. Bos AB, van Ballegooijen M, van Oortraarssen GJ, van Marie ME, Habberaa JD, Lynge E. Non-progression of cervical intraepithelial neoplasia estimated from population-screening data. Br J Cancer 1997;75:124-30.
38. Briggs A, Sculpher M. An introduction to Markov modelling for economic evaluation. Pharmacoeconomics 1998; 13:397-109.
39. van Ballegooijen M, Boer R, van Oortmarssen GJ, Koopmanschap MA, Lubbe JTh, Habbema JD. Bevolkingsonderzoek op baarmoederhalskanker: leeftijdsgrenzen en intervalien, Een geactualiseerde kos-ten-effectiviteitsanalyse. Rotterdam: Instituut Maatsehappelijke Gezondheidszorg, Erasmus Universiteit Rotterdam, 1993, 96.
40. Bulk S, van Kemenade FJ, Rozendaal L, Meijer CJ. The Dutch C1SOE-A framework for cytology reporting increases efficacy of screening upon standardisation since 1996. J Clin Pathol 2004;57: 388-93.
41. Garland SM, Hernandez-Avila M, Wheeler CM. Perez G. Harper DM, Leodolter S, Tang GW, Ferris DG, Steben M, Bryan J, Tadddeo FJ, Railkar R, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007:356:1928-1943.
42. Villa LL, Costa RL, Petta CA, Andrade RP, Paavonen J, Iversen OE, Olsson SE, Hove J, Steinwail M, Riis-Johamiesson G, Andersson-EU-strom A, Elfgren K, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 LI virus-like particle vaccine through 5 years of follow-up. Br J Cancer 2006;95: 1459-66.
43. van Ballegooijen M, Koopmanschap MA, Tjokrowardojo AJ, van Oortraarssen GJ. Care and costs for advanced cervical cancer. Eur J Cancer 1992;28A: 1703-8.
44. Meijer CJ, Berkhof J, Heideman DA, Snijders PJ. Cervical cancer prevention: who should receive vaccination? Nat Clin Pract Oncol 2008;5:12-13.
45. Liaw KL, Hildesheim A, Burk RD, Gravitt P, Wacholder S, Manos MM, Scott DR, Sherman ME, Kurman RJ, Glass AG, Anderson SM, Schiffman M. A prospective study of human papillomavirus (HPV) type 16 DNA detection by polymerase chain reaction and its association with acquisition and persistence of other HPV types. J Tnfect Dis 2001;183:8-15.
46. Rousseau MC, Pereira JS, Prado JC, Villa LL, Rohan TE, Franco EL. Cervical coinfection with human papillomavirus (HPV) types as a predictor of acquisition and persistence of HPV infection. J Infect Dis 2001;184:1508-17.
47. Boot HJ, Wallenburg I, de Melker HE, Mangen MJ, Gerritsen AA, van der Maas NA, Berkhof J, Meijer CJ, Kimman TG. Assessing the introduction of universal human papillomavirus vaccination for preadolescent girls in The Netherlands. Vaccine 2007;25:6245-56.
48. van Veen M, Koedijk F, van den Broek I, Op de Coul E, de Boer 1, van Sighem A, van der Sande MAB. Sexually transmitted infections in The Netherlands in 2006. RIVM rapport 210261003, Bilthoven, 2007.
49. van der Meijden WI, Notowicz A, Blog FB, Langley PC. A retrospective analysis of costs and patterns of treatment for external genital warts in the Netherlands. Clin Ther 2002;24; 183-96.
50. Giamiini SL, Hanon E, Moris P, Van MM, Morel S, Dessy F, Four-neau MA, Colau B, Suzich J, Losonksy G, Martin MT, Dubin G, et al. Enhanced humoral and memory B cellular immunity using HPV 16/18 LI VLP vaccine formulated with the MPL/alurainiutn salt combination (AS04) compared to aluminium salt only. Vaccine 2006:24(33-34);5937-49.
51. Fraser C, Tomassini JE, Xi L, Golra G, Watson M, Giuliano AR, Barr E, Ault KA. Modeling the long-term antibody response of a human papillomavirus (HPV) virus-like particle (VLP) type 16 prophvlactic vaccine. Vaccine 2007;25:4324-33.
52. Franco EL, Cuzick J, Hildesheim A, de Sanjose S. Chapter 20: issues in planning cervical cancer screening in the era of HPV vaccination. Vaccine 2006;24Suppl 3:S171-S177